September is Ovarian Cancer Awareness Month. Ovarian cancer affects 1 in 57 women in the United States and two thirds of those diagnosed are age 55 or older. The fifth leading cause of cancer-related deaths in women, diagnosis is often made after the disease has progressed since there are typically no distinct symptoms in its early stages. The symptoms often associated with ovarian cancer include abdominal or pelvic pain, bloating, difficulty eating/feeling full quickly and urinary urgency or frequency. Penn Medicine is making the prevention, early detection, and treatment of ovarian cancer a priority.
Penn Medicine researchers are working every day to create new therapies and increase each woman’s chance for a cure. The Penn Ovarian Cancer Research Center (OCRC) is developing new approaches to treating ovarian cancer to improve survival rates and enable women affected by this disease to live a better quality of life.
The OCRC utilizes personalized immunotherapy, which is an innovative treatment approach using the patient’s own tumor to derive cancer vaccines and cell–based therapeutics. The OCRC is currently enrolling patients in three phase I/II clinical trials for patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer.
Gynecologic oncology services at Penn Medicine
Clinical trials being done at Penn Medicine